Polyunsaturated fatty acids interfere with formation of the immunological synapse

J Leukoc Biol. 2005 May;77(5):680-8. doi: 10.1189/jlb.1104687. Epub 2005 Feb 9.

Abstract

Polyunsaturated fatty acids (PUFAs) exert inhibitory effects on T cell-mediated immune responses. Activation of T cells in vivo depends on formation of an immunological synapse (IS) at the T cell/antigen-presenting cell (APC) interface. Here, we analyzed effects of PUFA treatment on the formation of the IS and APC-induced human T cell activation. In T cells treated with the PUFA eicosapentaenoic (EPA; 20:5,n-3) and arachidonic acid (20:4,n-6), stimulated by superantigen-presenting cells or APCs, relocalization to the IS of distinct molecules [F-actin, talin, leukocyte functional antigen-1alpha, clusters of differentiation (CD)3epsilon] was inhibited markedly compared with cells treated with saturated fatty acid, whereas relocalization of protein kinase Ctheta to the IS remained unaffected. CD3-induced, sustained phosphorylation of nucleotide exchange factor Vav, which controls cytoskeletal rearrangements underlying IS formation, was significantly reduced in EPA-treated Jurkat and peripheral blood T cells. In addition, T cell raft disruption by methyl-beta-cyclodextrin treatment and experiments with a chimeric linker for activation of T cell proteins, which is resistant to PUFA effects on lipid rafts, revealed modifications of lipid rafts as a crucial factor for PUFA-mediated inhibition of APC-stimulated cytoskeletal rearrangements. Furthermore, the efficiency of T cell/APC conjugate formation was significantly reduced with EPA-treated T cells, as was stimulation of CD69 expression, which is not altered following antibody-mediated T cell activation. In conclusion, PUFA treatment of T cells qualitatively and quantitatively alters IS formation, thereby extending T cell signaling defects to pathways that are not intrinsically altered in PUFA-treated T cells when stimulated by antibodies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen-Presenting Cells / drug effects
  • Antigen-Presenting Cells / immunology*
  • Antigens, CD / immunology
  • Antigens, Differentiation, T-Lymphocyte / immunology
  • Arachidonic Acid / pharmacology*
  • CD3 Complex / immunology
  • Cell Communication / drug effects*
  • Cell Communication / immunology
  • Cell Cycle Proteins / immunology
  • Cytoskeletal Proteins / immunology
  • Eicosapentaenoic Acid / pharmacology*
  • Humans
  • Isoenzymes / immunology
  • Jurkat Cells
  • Lectins, C-Type
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology*
  • Membrane Microdomains / drug effects
  • Phosphorylation
  • Protein Kinase C / immunology
  • Protein Kinase C-theta
  • Proto-Oncogene Proteins / immunology
  • Proto-Oncogene Proteins c-vav
  • Receptors, Leukocyte-Adhesion / immunology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • beta-Cyclodextrins / pharmacology

Substances

  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • CD3 Complex
  • CD69 antigen
  • Cell Cycle Proteins
  • Cytoskeletal Proteins
  • Isoenzymes
  • Lectins, C-Type
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-vav
  • Receptors, Leukocyte-Adhesion
  • VAV1 protein, human
  • beta-Cyclodextrins
  • methyl-beta-cyclodextrin
  • Arachidonic Acid
  • Eicosapentaenoic Acid
  • PRKCQ protein, human
  • Protein Kinase C
  • Protein Kinase C-theta